Organon & Co. (OGN): Cash & Equivalents
$574.00M
As of 2025-12-31
$1.13B
As of 2026-06-30
-6.7%
3-year compound annual growth
+116.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $574.00M | -15.0% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $675.00M | -2.6% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $693.00M | -1.8% | 2025-11-10, Balance as of period end |
| 2022-12-31 | $706.00M | -4.2% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $737.00M | n/m | 2023-02-27, Balance as of period end |
| 2020-12-31 | $12.00M | n/a | 2022-03-21, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Organon & Co. (OGN) | 2025-12-31 | $574.00M | -15.0% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $4.55B | +73.1% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $545.00M | +16.5% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $1.39B | -42.3% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $1.31B | +10.8% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $1.66B | +71.5% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $1.31B | +39.1% |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $5.08B | +11.3% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $1.56B | -8.3% |
Compare OGN, ONC, ELAN, JAZZ side by side · Screen every company in Pharmaceutical Preparations ↗